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IntroductIon 
NTDs are diseases that affect many subtropical and tropical 
regions, such as Asia, Africa, and the Americas, where the most 
impoverished people live. According to a World Bank study, 
51 percent of the people of sub-Saharan Africa (SSA), a prime 
focus for NTDs, lives on less than US$1.25 a day, and 73% of 
the people lives on less than US$2 a day (Chen & Ravallion, 
2008). In relation to their outcome on health, NTDs lead to 
an immense economic and social burden arising from physical 
disabilities, loss of social status, social stigma, discrimination, 
blindness, disfigurement, growth failure, malnutrition, 
and impaired cognitive development. Such interrelated 
outcomes perpetuate the cycle of poverty by stopping people 
from leading productive lives and influencing households, 
communities, and countries as a whole negatively.
In the 2010 study, NTDs responsible for 26.06 million disability-
adjusted life years (DALYs) (95 percent confidence interval: 
20.30, 35.12), i.e., years of healthy life lost due to disability or 
premature life (Hotez et al., 2014). The DALY metric quantifies 
the burden of a disease as the number of healthy years of 
life lost to morbidity and mortality and is an internationally 
recognized summary measure of population health. It facilitates 
comparing the relative impact of diseases and risk factors over 
time (Devleesschauwer et al., 2014, Murray & Acharya, 1997). 
NTDs are also referred to as disablers rather than killers, and 
that’s why DALY metric is used as it has a direct co-relationship 
with morbidity rather than mortality. The biodiversity of NTDs 
indicates that the strategies for control or elimination are also 
very diverse. Several NTDs can be managed by drug treatment 
(preventive chemotherapy), on a nation or community scale, 
via mass drug administration (MDA) campaigns. Other 
NTDs require different control or elimination approaches and 
strategies, including specialized drugs and/or vector control 
(limiting or eradicating insects (pathogens transmitting flies and 
bugs) (Molyneux, 2013). Despite a range of strategies, several 
organizations, including the World Bank, Bill & Belinda Gates 
Foundation, United Kingdom Department for International 
Development, pharmaceutical companies, and government 
officials from donor and endemic countries chat together at an 
event entitled “Uniting to Combat NTDs: Ending the Neglect 
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More than a billion people-one-sixth of the earth’s population is infected with one or more neglected tropical diseases 
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the global burden of the diseases in terms of disability-adjusted life years (DALYs), years lived with disability (YLDs) 
and years of life lost (YLLs). This paper also reviews the negative impact of these diseases on global economies and 
discusses strategies for public health to prevent and eliminate these diseases, the achievements and challenges that 
can be achieved to address adversity there.
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and Reaching the 2020 Goals”, and set targeted goals for NTDs 
(Molyneux, 2012).
EPIdEMIologY And globAl burdEn 
scEnArIo
NTDs are biologically diverse, so they are found in regions 
with favorable conditions, such as poor hygienic conditions 
and sanitation. It is reckoned that 1·6 billion people worldwide 
are affected by NTDs, and 149 countries are endemic for at 
least one NTD (The Lancet Global Health, 2020). Bacteria, 
viruses, protozoa, and helminth parasites are the infectious 
agents responsible for NTDs. These agents are transmitted 
primarily through various vectors (flies, mosquitoes, sandflies, 
blackflies, etc.) and may cause NTDs when these vectors contact 
individuals. The major NTDs, their causative agents, and 
endemic regions are mentioned in table 1 (Hossain et al., 2017).
The Global Burden of Disease (GBD) study launched in 1990 as 
a single World Bank-commissioned analysis, now known as the 
GBD project, quantified the health impacts of more than 100 
diseases and injuries for eight regions of the world, providing 
estimates of morbidity and mortality by region, age, and sex. 
NTDs are among the world’s most familiar conditions, with 
over 2 billion cases, according to the 2013 GBD study (Table 2).
Since 1990, GBD 2013 shows some important and noteworthy 
changes in the incidence or prevalence of these diseases. The 
most remarkable is a 610 percent rise in the incidence of dengue 
fever, consistent with the extensive occurrence of this disease in 
the Americas, Asia, and Africa above what would be predicted 
due to shifts in population demographics. GBD 2013 showed 
that in prevalent cases of lymphatic filariasis, onchocerciasis, 
and vision loss attributable to trachoma, there were substantial 
reductions (approximately 30%-40%) (de Vlas et al., 2016). 
A 71% decrease in the number of cases of human African 
trypanosomiasis (HAT) infection is also included in the study 
(Steinmann et al., 2015).
The burden of NTD is represented by DALYs lost, which 
corresponds to the years of healthy life lost due to early death, 
ill-health or disability. Seventeen NTDs together forming the 
fourth largest disease burden of all communicable diseases, 
accounting for almost 46-57 million DALYs lost. When 
assessed using DALYs, NTDs become second only to HIV/AIDs 
and before malaria and tuberculosis in DALYs lost (WHO, 
2004). Seven of these 17 diseases are the most prevalent and 
are liable for most of the burden of NTD disease, affecting 
1.4 billion people globally. Infections with three soil-transmitted 
helminth (hookworm, ascariasis, and trichuriasis), lymphatic 
filariasis, onchocerciasis, trachoma, and schistosomiasis are 
all seven of these diseases (Norris et al., 2012). This burden is 
because these 17 neglected diseases are not killers but make 
people disable, leading them to become a burden on the earth. 
The major NTD burden is represented in table 3 by DALYs (Vos 
et al., 2015; Murray et al., 2015; Abubakar et al., 2015). The 
years of disability (YLD) and the years of life lost (YLL), the 
main component of DALYs, are both assessed in this table. For 
most neglected tropical diseases, YLDs contribute to a higher 
proportion of disability-adjusted life years than do YLLs, and 
the most common diseases (see Table 3) are also the ones that 
affect the most disability. In total, 8 million YLLs and 17 million 
YLDs were liable for NTDs in 2013 (Herricks et al., 2017). The 
GBD 2013 study compares the variation in DALYs since 2005 
(Table 3), and the change in percentage shows the small effort 
made to reduce the amount of DALYs.
In addition to the NTDs mentioned above, chikungunya has 
posed a threat to public health in recent years. The burden of 
chikungunya in India during the 2006 epidemic was calculated 
to be 25,588 DALYs lost, with a cumulative burden of 45.26 
DALYs per a one million-person population (Krishnamoorthy 
et al., 2009). The estimated total disability-adjusted life years 
lost for the 2014 Colombian epidemic was 40.44 to 45.14 per 
100k population (Cardona-Ospina et al., 2015). However, 
even DALYs do not reveal the entire story of the adverse 
consequences of NTDs. Some of the unique and potential 
shortcomings of Global Burden of Diseases Study 2010 have 
been outlined elsewhere (Byass et al., 2013). In addition, 
DALYs only assess direct health loss and, for instance, do not 
take into account the economic influence of the NTDs that 
results from adverse effects on child development and school 
attendance, agriculture (particularly zoonotic NTDs), and 
overall economic productivity (Miguel et al., 2004; Hotez et al., 
2009). Nor do disability-adjusted life years account for specific 
costs of surveillance, treatment, and prevention measures. Yet, 
economic influence has risen as an important feature of the 
neglected tropical diseases, which may trap people in a cycle 
of poverty and illness (Miguel et al., 2004; Hotez et al., 2009; 
King, 2010). Additional aspects not taken into account by the 
DALY metrics are the essential stigmatization components for 
many of the neglected tropical diseases and the spillover impacts 
to community and family members (Perera et al., 2007; Weiss, 
2008), loss of tourism (Mavalankar et al., 2009), and health 
system overloads (e.g., during dengue outbreaks). Ultimately, 
efforts to control and eliminate NTDs could generate economic 
and social benefits that are not necessarily reflected in the DALY 
metrics, particularly among the poor communities who are most 
affected (Hotez et al., 2009). 
PublIc HEAltH strAtEgIEs 
The WHO proposes a mixture of five approaches for the 
control and prevention of NTDs, which are implemented as 
per the epidemiology of the specific NTD. Intensified disease 
management (IDM), preventive chemotherapy (PCT), vector 
control, hygiene and sanitation, safe water, and public veterinary 
health are the strategies. The unprecedented decision by some 
pharmaceutical companies to donate ‘as many drugs as needed 
for as long as needed’ to help eradicate NTDs has changed the 
landscape of NTDs by trying to make the drugs available to the 
poorest nations, with PCT becoming the most common approach 
to treating the five major diseases (Samuels & Pose, 2013).
•	 PCT	 includes	 a	 single	dose	of	medication	once	or	 twice	
a year, typically given by the distribution of medicines on 
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NTDs Causative agent (s) Endemic areas
Bacterial infections
Buruli ulcer Mycobacterium ulcerans Australia, Guyana, Malaysia, Mexico, Peru, Sri Lanka, Papua 
New Guinea, West, and Central Africa
Bartonellosis Bartonella henselae, other Bartonella spp. Globally distributed 
Bovine tuberculosis Mycobacterium bovis Globally distributed (highest rates in developing countries)
Cholera Vibrio cholerae Southern and Central Africa, Dominican Republic, Haiti, 
Cambodia, Papua New Guinea, Thailand, Malaysia, Indian 
subcontinent
ETEC infection Enterotoxigenic Escherichia coli (ETEC) Globally distributed (highest rates in developing countries)
Salmonellosis Salmonella enteric serovars, S. enteritidis, S. 
typhimurium, S. typhi, S. paratyphi
Globally distributed (highest rates in developing countries)
Shigellosis Shigella dysenteriae, S. boydii, S. flexneri, S. sonnei Globally distributed (highest rates in developing countries)
Leprosy Mycobacterium leprae Brazil, China, Mozambique, Myanmar, Madagascar, 
Indonesia, India, Nepal, Philippines, Vietnam, Sudan, and 
other tropical and subtropical regions
Leptospirosis Leptospira interrogans Globally distributed (highest rates in developing countries)
Trachoma Chlamydia trachomatis Africa, Middle East, part of Asia, Australia, Mexico, South 
America
Treponematoses Treponema pallidum Globally distributed (highest rates in tropical regions)
Relapsing fever Borrelia recurrentis, B. duttoni, other Borrelia spp. Africa (highest rates), parts of Americas, Asia, Europe
Viral infections
Dengue Dengue fever virus (genus: Flavivirus) Indian subcontinent, South‑East Asia, Pacific Islands, Central 
and South America, Parts of Africa and Northern Australia
Yellow fever Yellow fever virus (genus: Flavivirus) South America, West, and Central Africa, occasionally in 
East Africa and Central America
Japanese encephalitis Japanese encephalitis virus (genus: Flavivirus) Indian subcontinent, South‑East Asia, intermittently in 
Northern Australia, and the Western Pacific
Chikungunya Chikungunya virus Africa, Southeast Asia, the Indian subcontinent, Pacific 
Region, and most probably in the (sub) tropical regions of the 
Americas
Rabies Rabies virus (genus: Lyssavirus) Globally distributed
Rift Valley fever Rift Valley fever virus (genus: Phlebovirus) Africa and Arabian Peninsula
Viral haemorrhagic fevers Arenaviridae: Lassa virus, Chapare virus, Guanarito 
virus, Junin virus, Machupo virus, Sabia virus
Bunyaviridae: Crimean‑Congo haemorrhagic fever 
virus (HFV), Hantaviruses, Puumala virus,
Filoviridae: Ebola virus, Marburg virus Flaviviridae: 
Omsk HFV, Kyasanur forest disease virus 
Certain viruses are endemic in certain areas. Lassa virus: 
Guinea, Liberia, Nigeria, Sierra Leone
Crimean‑Congo HFV: Africa, Arabian Peninsula, Bulgaria, 
Central Asia, Turkey, South‑West Russia
Hantavirus: Globally distributed; Filoviridae: Angola, Congo, 
Gabon, Kenya, Sudan, Uganda
Omsk HFV: West Siberia
Kyasanur forest disease virus: India
Helminth infections
Dracunculiasis Dracunculus medinensis Mali, South Sudan, Ethiopia
Cysticercosis/taeniasis Taenia solium, T. saginata, Diphyllobothrium latum Globally distributed
Enterobiasis Enterobius vermicularis Globally distributed (highest rates in developing countries)
Echinococcosis Echinococcus granulosus, E. multilocularis Globally distributed
Intestinal fluke infection Echinosoma spp. Fasciolopsis buski, Metagonimus spp. Bangladesh, India, Malaysia, Indonesia, Taiwan, China, 
Philippines, Vietnam, Thailand, Cambodia
Fascioliasis Fasciola gigantic, F. hepatica Bolivia, Cuba, Chile, Ecuador, Egypt, Iran, France, Portugal, 
Peru, Spain
Clonorchiasis Clonorchis sinensis China, South Korea, Taiwan
Paragonimiasis Paragonimus spp. India, Pakistan, Nepal, Sri Lanka, Malaysia, Thailand, 
Vietnam, Laos, Philippines, Taiwan, China, South Korea, 
Japan, Cameroon, Nigeria, Liberia, Costa Rica, Ecuador, 
Guinea, Guatemala, Gabon, Peru, Panama, Mexico
Opisthorchiasis Opisthorchis felineus, O. viverrini Thailand, Vietnam, Laos, Ukraine, Siberia, Kazakhstan, 
Russia
Lymphatic filariasis Wuchereria bancrofti, Brugia malayi, B. timori Africa, Asia, Central and Southern America
Loiasis Loa loa Central and West Africa
Mansonellosis Mansonella perstans, M. streptocerca, M. ozzardi Caribbean, Central and South America, Sub‑Saharan Africa
Schistosomiasis Schistosoma haematobium, S. guineensis, S. 
intercalatum, S. japonicum, S. mansoni, S. mekongi
Sub‑Saharan Africa, Parts of Central and West Africa, some 
Caribbean islands, China, Indonesia, Philippines, Cambodia, 
Laos
Onchocerciasis Onchocerca volvulus Africa, a small part of Central and Southern America
Ascariasis Ascaris lumbricoides Globally distributed
Hookworm infection Ancylostoma duodenale, Necator americanus Globally distributed
Strongyloidiasis Strongyloides stercoralis Globally distributed
Table 1: List of NTDs, their causative agent (s), and the potential endemic areas of these NTDs (Hossain et al., 2017)
(Contd...)
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NTDs Causative agent (s) Endemic areas
Trichuriasis Trichuris trichiura Globally distributed
Toxocariasis Toxocara canis, T. cati Globally distributed
Trichinellosis Trichinella spiralis, other Trichinella spp. Globally distributed
Ectoparasitic infections
Scabies Sarcoptes scabiei Globally distributed (highest rates in tropical and subtropical 
regions)
Myiasis Parasitic fly larvae (Calliphoridae Oestridae, 
Sarcophagidae and others)
Globally distributed (highest rates in tropical and subtropical 
regions)
Fungal infections
Mycetoma (Madura foot) Various fungi (eumycetoma) and 
bacteria (actinomycetoma, pseudomycetoma)
Africa, India, Central, and South America
Paracoccidiomycosis Paracoccidioides brasiliensis Argentina, highest rates in Brazil (80%), Colombia, Ecuador, 
Mexico, parts of Central America, Venezuela
Protozoal infections
Chagas disease Trypanosoma cruzi Latin America
Human African trypanosomiasisTrypanosoma brucei gambiense, T. brucei rhodesiense Africa
Amoebiasis Entamoeba histolytica Globally distributed (highest rates in developing countries) 
Giardiasis Giardia intestinalis Globally distributed (highest rates in developing countries)
Leishmaniasis Visceral leishmaniasis: Leishmania donovani, L. chagasi, 
L. infantum Mucocutaneous leishmaniasis: L. major, L. 
tropica, L. mexicana, L. braziliensis
Indian subcontinent, Asia, Africa, South Africa, 
Mediterranean basin
Table 1: (Continued)
Table 2: Prevalent cases of NTDs in 2013 and percent change from 1990 to 2013 according to the Global Burden of Disease 
Study (GBD) 2013 (Vos et al., 2015)





Foodborne trematodiases 80.2 51.1%
Dengue*┼ 58.4 610.9%
Lymphatic filariasis 43.9 −32.1%
Onchocerciasis 17.0 −31.2%
Chagas disease 9.4 22.4%
Cutaneous/mucocutaneous leishamaniasis 3.9 174.2%
Trachoma┼ 2.4 −39.2%
Cysticercosis┼ 1.0 −26.3%
Cystic echinococcosis┼ 0.8 −15.4%
Leprosy 0.7 61.3%
Visceral leishmaniasis 0.1 35.1%
Rabies*┼ 0.02 −40.4%
African trypanosomiasis 0.02 −71.1%
Other NTDs 59.7 −5.0%
Total cases 2,322 NA
Additional NTDs Prevalent cases (in millions) in 2013 Percent change since 1990
Trichomoniasis 67.1 45.6%
Scabies 66.1 24.8%
Typhoid fever* 11.0 −19.9%
Paratyphoid fever* 6.4 −27.9%




Total cases of additional neglected diseases 160.2 NA
*Incident cases in 2013 rather than prevalent cases, ┼Symptomatic cases only.
See GBD 2013 capstone manuscript on prevalence, incidence, and years lived with a disability (YLDs) for detail on percent (%) change 
calculations (Vos et al., 2015). All data provided in this table (exception of cholera, rabies, amoebiasis and cryptosporidiosis) are also obtainable on 
the website of the Institute for Health Indicators and Evaluation (IHME) and have been previously published in Vos et al. (2015). Abbreviations: NA, 
non‑applicable
a wide scale, known as mass drug administration (MDA). 
Not fewer than 65%-80% of the total population living in 
endemic areas must take the medication for MDA to be 
effective. As such, it is oftentimes administered by teachers 
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Table 3: Leading causes of disability‑adjusted life years (DALYs) resulting from the NTDs according to the Global Burden of 
Diseases Study (GBD) 2013 with attributing years lived with disability (YLDs) and years of life lost (YLLs) (Vos et al., 2015; 
Murray et al., 2015; Abubakar et al., 2015)
NTDs DALYs (in millions) in 
2013
Percent change for 
DALYs 2005‑2013
YLDs (in millions) 
in 2013
YLLs (in millions) 
in 2013
Visceral leishmaniasis 4.24 8.7% 0.008 4.23
Foodborne trematodiases 3.63 14.6% 3.63 0
Schistosomiasis 3.06 −13.9% 2.86 0.2
Hookworm 2.18 −0.5% 2.18 0
Lymphatic filariasis 2.02 −14.3% 2.02 0
Ascariasis 1.27 −29.0% 0.93 0.34
Rabies 1.24 −14.6% 0.0001 1.24
Onchocerciasis 1.18 −19.4% 1.18 0*
Dengue 1.14 17.0% 0.56 0.58
Trichuriasis 0.58 −12.3% 0.58 0
African trypanosomiasis 0.39 −54.3% 0.005 0.38
Chagas disease 0.34 4.6% 0.10 0.24
Cysticercosis 0.34 −16.4% 0.31 0.03
Cystic echinococcosis 0.18 −14.1% 0.08 0.1
Trachoma 0.17 −18.1% 0.17 0
Cutaneous and mucocutaneous leishmaniasis 0.04 35.9% 0.04 0
Leprosy 0.04 8.6% 0.04 0
Other NTDs 3.13 −11.8% 2.26 0.87
Total NTDs 25.17 NA 16.95 8.21
Additional neglected diseases DALYs (in millions) in 
2013
Percent change for 
DALYs 2005‑2013
YLDs (in millions) 
in 2013
YLLs (in millions) 
in 2013
Typhoid fever 11.13 −13.7% 0.16 10.97
Cholera 5.17 −20.1 0.04 5.13
Paratyphoid fever 3.82 −8.0% 0.04 3.78
Cryptosporidiosis 3.46 −29.6 0.19 3.27
Venomous animal contact 3.00 −3.4% 0.15 2.85
Scabies 1.71 4.8% 1.71 0
Amoebiasis 0.38 −23.8% 0.04 0.34
Trichomoniasis 0.11 8.2% 0.11 0
Total deaths from additional neglected diseases 28.78 NA 2.44 26.34
See GBD 2013 capstone manuscript on DALYs for detail on percent (%) change calculations (Murray et al., 2015). The estimates presented in this 
table are also obtainable on the website of the Institute for Health Metrics and Evaluation (IHME) and were previously published in (Vos et al., 2015; 
Murray et al., 2015; Abubakar et al., 2015). Information on YLDs and DALYs for Cryptosporidiosis, Cholera, and Amoebiasis is not obtainable from 
the website of IHME or capstone papers. Abbreviations: NA, non‑applicable
and community volunteers, facilitating delivery to vast 
numbers of people in rural areas as well. Some individuals 
are not eligible to receive these drugs – children under the 
age of two or five years, the very sick, or pregnant women 
(Samuels & Pose, 2013).
•	 IDM	includes	care	 for	 infected	persons	and	those	at	 risk	
of infection. This intervention is the prime strategy for 
the control of NTDs for which no preventive medicines 
are obtainable, such as Chagas disease, Buruli ulcer, 
leishmaniasis, human African trypanosomiasis, leprosy, and 
yaws (Samuels & Pose, 2013).
•	 The	use	 of	 pesticides	 is	 also	 needed	 to	 combat	 vector-
borne diseases transmitted by snails, insects, or crustaceans 
(Samuels & Pose, 2013).
•	 Management	of	vectors	is	strengthened	by	the	provision	of	
sanitation, hygiene, and safe water and close cooperation 
within sectors responsible for health, agriculture, irrigation 
and environment (Samuels & Pose, 2013).
•	 Finally,	veterinary	public-health	interventions	are	also	crucial	
in tackling neglected tropical diseases because zoonotic 
diseases (e.g., anthrax, bovine tuberculosis, cysticercosis, 
brucellosis, echinococcosis, zoonotic trypanosomiasis, 
and rabies) are responsible for much of the mortality and 
morbidity arising from NTDs (Samuels & Pose, 2013).
The major NTDs and intervention strategies are listed in 
table 4. These strategies can control or eliminate the adversity 
of neglected tropical diseases by 2020 if properly implemented, 
although some challenges need to be overcome to achieve the 
goal by 2020.
AcHIEvEMEnts 
WHO has recorded incredible achievements in combating 
neglected tropical diseases since 2007. An estimated 1 billion 
people received treatment in 2015 alone. The WHO report, 
Integrating NTDs in global health and development, reveals 
how generous donations of medicines, strong political support, 
and improvements in living standards have guided to sustained 
expansion of disease control programmes in countries where 
these diseases are most prevalent (WHO, 2017).
Since 2007, when a group of global collaborators met to agree to 
tackle neglected tropical diseases, a number of international and 
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local partners have partnered alongside ministries of health in 
endemic nations to provide quality-assured medicines, and offer 
people with care and long-term management. In 2012, Partners 
endorsed a WHO NTD roadmap, contributing additional 
assistance and resources to eliminate 10 of the most prevalent 
NTDs (WHO, 2017).
Key achievements of this roadmap of the WHO NTD include 
(WHO, 2017):
•	 In 2015 alone, at least 1000 million people were treated for 
NTD.
•	 0.556 billion individuals obtained preventive treatment for 
lymphatic filariasis (elephantiasis).
•	 More than 0.114 billion individuals received treatment for a 
disease caused by the filarial nematode Onchocerca volvulus 
(onchocerciasis, or river blindness: 62% of those needing it).
•	 In 2016, only 25 human Guinea-worm disease cases were 
recorded, placing eradication within reach.
•	 HAT (sleeping sickness) cases have been lowered from 
37,000 new cases in 1999 to well below 3000 in 2015.
•	 Trachoma – the world’s top infectious cause of blindness 
– has been eliminated as a public health issue in Morocco, 
Mexico, and Oman. More than 185 million trachoma 
patients had surgery worldwide for trichiasis and antibiotics 
had been received by 56 million individuals in 2015 alone.
•	 Visceral leishmaniasis: 100% of Nepal’s districts, 97% of 
Bangladesh’s sub-districts, and 82% of India’s sub-districts 
reached the elimination target in 2015.
•	 Only 12 confirmed human deaths were due to rabies in the 
WHO Region of the Americas in 2015, putting the region 
close to the goal of eliminating rabies in humans by 2015.
cHAllEngEs
Despite all the success achieved, NTDs remain worrying in 
many third-world people who is still live below the poverty line 
and are deprived of all the facilities necessary to lead a healthy 
life. WHO reports that there are still about 2.4 billion people 
without adequate sanitation facilities, such as toilets and latrines 
(Hutton et al., 2017), while more than 660 million people still 
drink water from “unimproved” sources such as surface water 
(UNICEF & WHO, 2015). Reports also suggest that millions 
of people do not have access to NTD drugs, and prevention 
programs remain inadequately funded. 
Failure to distribute drugs adequately is also a major challenge in 
this term. A better method of delivering and distributing drugs 
should need to be introduced. There are still some NTDs such 
as dengue fever, chikungunya which cause havoc in populations, 
and the recent outbreaks of zika virus and its complications 
create a massive concern to the associated authorities to 
reconsider and introduce new diagnostic tools, medicines, and 
insecticides to improve its control.
To overcome these challenges, strengthening joint efforts 
between stakeholders, along with increased support, is a 
prerequisite for ensuring the success of NTD programs in 
achieving the goal. It is now imperative to develop the best 
possible tools to defeat these diseases and make them accessible 
to workers on the ground. 
conclusIon 
The main goals of this review are to learn about the various 
neglected tropical diseases and how they are distributed which 
results in harming our socio-economic development and 
global economy. NTDs are more common in regions where 
living standards are not acceptable and where sources of pure 
drinking water and foods are not commonly available. Though 
these diseases are not considered as lethal but can lead a life to 
disability. Moreover, a lot of burdens are created each year by 
those NTDs which have a bad impact on the global economy. 
A must need attention is required to prevent them and basic 
treatments will be focused on preventive measures rather than 
medication. If we desire to get rid of these diseases, need to have 
better living conditions and ensuring of proper food and drink 
sources. Vector control is also a prerequisite since most NTDs 
are spread by vectors. Finally and foremost, what we need to 
do is to introduce new diagnostic tools and a better method of 
delivering drugs and improve the living conditions of people.
Table 4: The intervention strategies of the major neglected tropical diseases, where elimination refers to elimination as a public 
health problem (Hollingsworth et al., 2015)
Disease Interventions WHO target for 2020
Preventive chemotherapy (PCT) diseases, controlled by mass drug administration (MDA) programmes
Lymphatic filariasis (elephantiasis) Annual/biannual MDA (ivermectin, albendazole and DEC), vector control 
through insecticide‑treated bed nets or spraying
Global elimination 
Onchocerciasis (river blindness) MDA (ivermectin) and vector control Country elimination
Schistosomiasis (bilharzia) MDA (praziquantel) to school‑age children and high‑risk adults, along with 





MDA (albendazole, mebendazole) treatment of school‑aged children. 




Blinding trachoma MDA (azithromycin) and surgery, along with improved hygiene Global elimination
Intensified disease management (IDM) diseases, controlled by increased diagnosis and management of cases
Chagas disease Spraying with indoor residual insecticides, housing improvements Regional elimination
HAT (sleeping sickness), Gambian form Treatment, active/mass screening and vector control with tsetse targets Global elimination
Leprosy Early diagnosis and treatment Global elimination
Visceral leishmaniasis (kala‑azar) in the 
Indian sub‑continent
Indoor residual spraying of insecticides, insecticide‑treated bed nets, active case 
detection, rapid diagnosis and treatment
Regional elimination
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